EICHOR
● Completed
A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma
Condition: Asthma · Sponsor: Amgen
About this study
The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (154)
| Kern Research Inc | Bakersfield, California, United States | — |
| Orso Health Inc | La Jolla, California, United States | — |
| Imax Clinical Trials | La Palma, California, United States | — |
| Antelope Valley Clinical Trials | Lancaster, California, United States | — |
| Downtown Los Angeles Research Center, Inc | Los Angeles, California, United States | — |
| NewportNativeMD, Inc | Newport Beach, California, United States | — |
| University of California Irvine | Orange, California, United States | — |
| Apex Clinical Research | San Diego, California, United States | — |
| Allergy and Asthma Clinical Research | Walnut Creek, California, United States | — |
| Allianz Research Institute Westminster | Westminster, California, United States | — |
| St Francis Medical Institute | Clearwater, Florida, United States | — |
| BioMed Research Institute | Miami, Florida, United States | — |
+ 142 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06376045